Integrating socio-economic support into drug-resistant TB care to optimise treatment outcomes

Limo, J.; Pahe, C.; Kathure, I.; Ndungu, L.; Mahihu, A.; Mwashumbe, C.; Mueni, E. and Momanyi, H.

2025-01_QA Notice_USFDA Warning letter_Mylan Indore Pithampur site

Enhancing tuberculosis case notifications through mapping sales of medicine in the private sector: a quasi-experimental study in Punjab province, Pakistan

Beatrice Kirubi, Kinz Ul Eman, Usman R. Lodhi, Razia K. Fatima, Ghulam Nabi Kazi, Tahmeena Tahmeena, Syed Karam Shah and Jacob Creswell

ITB document ITB-Iplus/GDF-MED/2024/3

Annex L. TB medicines target prices ITB-Iplus/GDF-MED/2024/3

Annex K. Form for Requests for Clarifications or Complaints ITB-Iplus/GDF-MED/2024/3

Annex J. Global Drug Facility artwork development guidelines ITB-Iplus/GDF-MED/2024/3

Annex I. GMSD address list ITB-Iplus/GDF-MED/2024/3

Annex H. Indicative non-binding estimated quantities ITB-Iplus/GDF-MED/2024/3

Annex G. GDF access to supplier information for WHO PQP and ERP assessed TB medicines ITB-Iplus/GDF-MED/2024/3